- Home
- IVT vs GLPG Comparison
IVT vs GLPG Comparison
Compare IVT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- GLPG
- Stock Information
- Founded
- IVT 2005
- GLPG 1999
- Country
- IVT United States
- GLPG Belgium
- Employees
- IVT N/A
- GLPG N/A
- Industry
- IVT Real Estate Investment Trusts
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- IVT Real Estate
- GLPG Health Care
- Exchange
- IVT Nasdaq
- GLPG Nasdaq
- Market Cap
- IVT 2.2B
- GLPG 2.1B
- IPO Year
- IVT N/A
- GLPG 2005
- Fundamental
- Price
- IVT $29.98
- GLPG $33.36
- Analyst Decision
- IVT Buy
- GLPG Sell
- Analyst Count
- IVT 5
- GLPG 4
- Target Price
- IVT $32.25
- GLPG $25.33
- AVG Volume (30 Days)
- IVT 374.2K
- GLPG 255.3K
- Earning Date
- IVT 10-28-2025
- GLPG 10-29-2025
- Dividend Yield
- IVT 3.18%
- GLPG N/A
- EPS Growth
- IVT 1533.99
- GLPG N/A
- EPS
- IVT 1.47
- GLPG N/A
- Revenue
- IVT $287,075,000.00
- GLPG $323,674,692.00
- Revenue This Year
- IVT $9.93
- GLPG N/A
- Revenue Next Year
- IVT $8.00
- GLPG N/A
- P/E Ratio
- IVT $20.31
- GLPG N/A
- Revenue Growth
- IVT 9.17
- GLPG 5.43
- 52 Week Low
- IVT $25.21
- GLPG $22.36
- 52 Week High
- IVT $31.65
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- IVT 69.45
- GLPG 59.82
- Support Level
- IVT $29.32
- GLPG $30.88
- Resistance Level
- IVT $30.03
- GLPG $33.25
- Average True Range (ATR)
- IVT 0.46
- GLPG 0.75
- MACD
- IVT 0.08
- GLPG -0.02
- Stochastic Oscillator
- IVT 82.74
- GLPG 97.25
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.